Effect of endogenous Clostridium difficile toxin antibodies on recurrence of C. difficile infection

eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/ Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

[1]  M. Salavert,et al.  Prediction of recurrent clostridium difficile infection at the bedside: the GEIH-CDI score. , 2017, International journal of antimicrobial agents.

[2]  Mark A. Miller,et al.  Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Xuemei Zhao,et al.  Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection. , 2016, Bioanalysis.

[4]  L. Valiquette,et al.  Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Rabih Nayfe,et al.  Factors Predicting Recurrence of Clostridium difficile Infection (CDI) in Hospitalized Patients , 2015, Journal of Investigative Medicine.

[6]  D. Leffler,et al.  Clostridium difficile infection. , 2015, The New England journal of medicine.

[7]  L. Valiquette,et al.  Risk Factors for Recurrence, Complications and Mortality in Clostridium difficile Infection: A Systematic Review , 2014, PloS one.

[8]  T. Louie,et al.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[10]  Roger Baxter,et al.  Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). , 2010, Vaccine.

[11]  M. Hu,et al.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. , 2009, Gastroenterology.

[12]  C. Kelly,et al.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.

[13]  C. Kelly,et al.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. , 2000, The New England journal of medicine.

[14]  K. Carroll,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Matthew Sims,et al.  Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. , 2017 .

[16]  J. Stockman.  Treatment with Monoclonal Antibodies against Clostridium difficile Toxins , 2011 .